ArticleLa Radiologia medica2020
Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Article in La Radiologia medica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Multiparametric MRI findings, PI-RADS scores, and gleason scores in prostate cancer patients at Kumasi, Ghana: a cross-sectional analysis.BMC medical imaging · 2026Article
- RADS ALPHABET: news and tips for young and general radiologists.Insights into imaging · 2026Article
- The Utility of Transperineal Template Saturation Biopsy in the Detection of Clinically Significant Prostate Cancer.Advances in urology · 2025Article
- Textural Features of MR Images Correlate with an Increased Risk of Clinically Significant Cancer in Patients with High PSA Levels.Journal of clinical medicine · 2023Article
- Role of magnetic resonance imaging for preoperative prediction of early biochemical failure in localized prostate cancer.Quantitative imaging in medicine and surgery · 2023Article
- Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions.Frontiers in oncology · 2023Article
- Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel.Cancers · 2022Review
- Article
- Dynamic contrast-enhanced (DCE) imaging: state of the art and applications in whole-body imaging.Japanese journal of radiology · 2022Review
- Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.La Radiologia medica · 2021Article
- Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate the relationship between the serum PSA level, Gleason score (GS), PI-RADS v2 score, tumor ADC MATERIALS AND
methodsThe mpMRI examinations of the patients who underwent RP due to PCa were retrospectively evaluated. According to the final GS, the lesions were divided into two groups as clinically significant (GS ≥ 7) and insignificant (GS ≤ 6). The PSA value, tumor ADC
resultsIn both central and peripheral gland tumors, there was a correlation between the PSA level, tumor diameter, PI-RADS score, ADC
conclusionThe current PI-RADS v2 scoring system can be inadequate in distinguishing clinically significant and insignificant groups in central gland tumors. A separate cut-off value of the tumor diameter should be determined for central and peripheral gland tumors. Tumor ADC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.